Clinical trial · Interventional
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
Phase II Trial of Pre-Operative Chemoradiation Plus Bevacizumab, Followed by Surgery, and Post-Operative Adjuvant Bevacizumab for Patients With Loco-Regional Esophageal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was unable the accrue the required number of patients within a reasonable time.
Summary
Brief summary (as posted)
The purpose of this study is to determine whether bevacizumab can improve the outcome of treatment for patients with esophageal cancer whose disease is confined to the esophagus or the closely surrounding lymph nodes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Loco-regional Esophageal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-Fluorouracil | Drug | Fluorouracil | ALIAS |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Esophagectomy | Procedure | — | UNRESOLVED |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
| Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Bevacizumab
- interventionNames
- Drug: Bevacizumab
- Drug: Paclitaxel
- Drug: Cisplatin
- Drug: 5-Fluorouracil
- Radiation: Radiation Therapy
- Procedure: Esophagectomy
Primary outcomes (1)
- measure
- Disease Free Survival Time
- timeFrame
- 5 years
- description
- The primary outcome that will be measured is the length of time that patients are alive without recurrence of cancer following this therapy.
Secondary outcomes (2)
- measure
- The Number of Patients Cancer Free at the Time of Surgery
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. No prior treatment for esophageal cancer 2. No prior radiation to the chest or upper abdominal area 3. No prior treatment with an EGFR inhibitor or an anti-angiogenic agent 4. Disease should be limited to the esophagus and regional lymph nodes - Exclusion Criteria: 1. History of stroke 2. History of heart attack 3. Inadequately controlled high blood pressure
References
Publications (0)
Data not yet available